Publications by authors named "Burak Doganyigit"
Article Synopsis
- - The study investigates the urgent need for effective ways to diagnose and track Alzheimer’s disease (AD) by focusing on memory issues and brain changes, particularly in those with mild to moderate AD dementia (ADD).
- - Researchers followed 104 ADD patients over several years using MRI scans and cognitive tests to analyze brain structure and cognitive decline, finding a strong link between gray matter loss in the temporal lobe and difficulties with word learning.
- - The findings indicate that certain brain atrophy patterns, specifically in the temporal lobe, combined with specific cognitive test deficits, could help predict quicker cognitive decline in AD patients.
Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population.
Michaela Defrancesco Elke R Gizewski Stephanie Mangesius Malik Galijasevic Irene Virgolini Burak Doganyigit
BJPsych Open
September 2024
Article Synopsis
- - The study evaluated the real-world applicability of lecanemab, a newly FDA-approved monoclonal antibody for Alzheimer's-related dementia, by analyzing data from a memory clinic between January 2022 and July 2023.
- - Out of 587 out-patients, only 4.3% with dementia and 1.5% with mild cognitive impairment (MCI) qualified for lecanemab treatment based on its eligibility criteria, while a notable percentage of others lacked necessary amyloid status.
- - Findings indicate that despite having a specialized clinic dedicated to dementia diagnostics, the majority of patients do not qualify for lecanemab, highlighting challenges in applying clinical trial criteria to real-world populations.